AtriCure (NASDAQ:ATRC) Announces Earnings Results

Key Points

• AtriCure beat Q1 expectations with $141.2 million in revenue (up ~14% YoY) and $0.00 EPS, drove adjusted EBITDA to $17.1 million, and reiterated full‑year revenue guidance of $600–$610 million while updating FY2026 EPS to 0.000–0.040.
• The pivotal BoxX‑NoAF randomized trial is enrolling ~300 of 960 patients and is running about a year ahead of plan, with full enrollment expected by end‑2026 — a successful readout could materially expand the addressable market for postoperative AF prevention.
• Operational headwinds persist as U.S. minimally invasive ablation sales fell ~25% YoY and international growth was uneven, and accelerated BoxX‑NoAF enrollment will raise R&D spend over the next three quarters (management expects to absorb the incremental cost).

AtriCure (NASDAQ:ATRC - Get Free Report) posted its quarterly earnings data on Tuesday. The medical device company reported $0.00 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.07, reports. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The company had revenue of $141.25 million during the quarter, compared to analyst estimates of $139.75 million. During the same period in the prior year, the firm earned ($0.14) earnings per share. The business's quarterly revenue was up 14.3% on a year-over-year basis. AtriCure updated its FY 2026 guidance to 0.000-0.040 EPS.

Here are the key takeaways from AtriCure's conference call:

• Q1 worldwide revenue of $141.2 million (up ~14% YoY) drove a near-doubling of adjusted EBITDA to $17.1 million and a breakeven net income, with gross margin improving to 77.4% (+246 bps).
• The BoxX-NoAF randomized trial is enrolling ~300 of 960 patients and is tracking ~1 year ahead of plan, with full enrollment expected around the end of 2026 — a catalytic data event that could materially expand the addressable market for postoperative AFib prevention.
• Product momentum is driving growth — pain management (cryoSPHERE MAX) grew ~28% and contributed ~70% of pain sales, while open ablation (EnCompass Clamp) and appendage management (AtriClip FLEX‑Mini, which represented ~40% of U.S. open appendage revenue) continue to gain adoption.
• Management reiterated full‑year guidance of $600–$610 million revenue and $80–$82 million adjusted EBITDA, but accelerated BoxX-NoAF enrollment will raise R&D spending over the next three quarters (company expects to absorb the incremental cost).
• Headwinds remain in minimally invasive (MIS) ablation — U.S. MIS sales fell ~25% YoY — and international growth is uneven (11.5% reported, 3.3% constant currency) due to U.K. uncertainty and lumpy APAC distributor orders.

AtriCure Stock Performance

ATRC stock traded down $0.21 during midday trading on Thursday, hitting $27.80. 1,005,702 shares of the company traded hands, compared to its average volume of 712,631. AtriCure has a twelve month low of $26.62 and a twelve month high of $43.18. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13. The business has a 50 day simple moving average of $29.30 and a 200-day simple moving average of $34.35. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -278.00 and a beta of 1.28.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ATRC shares. UBS Group dropped their target price on AtriCure from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Wednesday, February 18th. Weiss Ratings downgraded AtriCure from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday. Canaccord Genuity Group upped their target price on AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday. JPMorgan Chase & Co. downgraded AtriCure from an "overweight" rating to a "neutral" rating and set a $36.00 target price on the stock. in a report on Wednesday, February 11th. Finally, BTIG Research reiterated a "buy" rating and issued a $54.00 target price on shares of AtriCure in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $48.71.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider directly owned 96,875 shares of the company's stock, valued at approximately $2,889,781.25. This represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.00% of the company's stock.

Institutional Investors Weigh In On AtriCure

Hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC increased its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after buying an additional 429 shares in the last quarter. Scotia Capital Inc. increased its stake in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company's stock valued at $1,328,000 after buying an additional 457 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company's stock valued at $314,000 after buying an additional 579 shares in the last quarter. Mackenzie Financial Corp increased its stake in shares of AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company's stock valued at $545,000 after buying an additional 683 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of AtriCure by 1.6% in the second quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company's stock valued at $1,475,000 after buying an additional 691 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.